Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.
PARTNERS
ABOUT US
PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.
LATEST NEWS
Innovations Advanced by M&A: A First-in-Class Therapy for Myasthenia Gravis
The 2020 acquisition of Momenta Pharmaceuticals by Johnson & Johnson (J&J) was critical to advancing IMAAVY (nipocalimab), a first-in-class therapy for generalized myasthenia gravis (gMG).
Life Sciences M&A Provides a Critical Path for Innovation Amid Declining Biotech Funding
As small and mid-sized biotech companies are facing increasing funding pressures, life sciences mergers and acquisitions (M&A) have emerged as an increasingly important mechanism to sustain innovation and advance new therapies.
PULSE Urges FTC, DOJ To Reconsider Policies that Deter Pro-Competitive Life Sciences M&A
In comments to the Department of Justice (DOJ)’s Anticompetitive Regulations Task Force, PULSE urged DOJ and Federal Trade Commission (FTC) officials to revisit antitrust policies that are deterring pro-competitive life sciences M&A.